<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03848793</url>
  </required_header>
  <id_info>
    <org_study_id>HS-20004-201</org_study_id>
    <nct_id>NCT03848793</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.</brief_title>
  <official_title>A Phase 2, Multiple Centers, Double-blind, Placebo-Controlled, Randomised Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of Noiiglutide Injection as
      mono-therapy with different doses in subjects with type 2 diabetes compared to placebo for 16
      weeks.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>16 weeks treatment</time_frame>
    <description>Estimated mean change from baseline in HbA1c at week 16. The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose</measure>
    <time_frame>16 weeks treatment</time_frame>
    <description>Estimated mean change from baseline in FPG at week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>16 weeks treatment</time_frame>
    <description>Estimated mean change from baseline in Body Weigh at week 16.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>HS-20004 or placebo treatment (Low dose)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HS-20004 or placebo SC once daily (Low dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS-20004 or placebo treatment (median dose 1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HS-20004 or placebo SC once daily (median dose 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS-20004 or placebo treatment (median dose 2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HS-20004 or placebo SC once daily (median dose 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS-20004 or placebo treatment (high dose)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HS-20004 or placebo SC once daily (high dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-20004</intervention_name>
    <description>treatment</description>
    <arm_group_label>HS-20004 or placebo treatment (Low dose)</arm_group_label>
    <arm_group_label>HS-20004 or placebo treatment (high dose)</arm_group_label>
    <arm_group_label>HS-20004 or placebo treatment (median dose 1)</arm_group_label>
    <arm_group_label>HS-20004 or placebo treatment (median dose 2)</arm_group_label>
    <other_name>Noiiglutide Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes diagnosed for more than 3 months

          -  HbA1c between 7.5 and 11.0 % (inclusive), and FPG ≥9.0mmol/l

          -  Body Mass Index (BMI) between 23 and 35 kg/m2(inclusive)

        Exclusion Criteria：

          -  History or family history of drug allergy

          -  Subjects treated with any other anti-diabetes drug within 8 weeks before screening

          -  Participation in any other clinical trial of an investigational medicinal product
             within 3 months before screening

          -  Smoker or alcohol abuse

          -  Currently use or plan to use systemic corticosteroid

          -  History of recurrent severe hypoglycemia

          -  Type 1 diabetes or secondary diabetes mellitus

          -  Uncontrolled active or untreated hypertension

          -  History of pancreatitis (acute or chronic)

          -  Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary
             Thyroid Carcinoma (MTC)

          -  Serious unconscious hypoglycemia history

          -  Within the past 6 months before screening any of the following: coronary artery
             revascularization, patients presently classified as being in New York Heart
             Association (NYHA) Class III or IV, myocardial infarction, stroke or unstable angina
             and/or persistent and clinically significant arrhythmias

          -  Female subject of childbearing potential who does not use an acceptable method of
             birth control, is pregnant or planning a pregnancy, or breastfeeding, or male subject
             who does not use an acceptable method of birth control

          -  Subject was not used for the study as determined by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JIE WU</last_name>
    <phone>+868936619898</phone>
    <email>wujie@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AN PEI</last_name>
    <phone>+8618036617508</phone>
    <email>anpei@hrglobe.cn</email>
  </overall_contact_backup>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

